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Background:  Foot-and-mouth disease virus (FMDV) is a 
small single-stranded RNA virus which belongs to the family 
Picornaviridae, genus Apthovirus. It is a principal cause of 
FMD which is highly contagious in livestock. In a wild type vi-
rus infection, infected animals usually elicit antibodies 
against structural and non-structural protein of FMDV. A 
structural protein, VP1, is involved in neutralization of virus 
particle, and has both B and T cell epitopes. A RNA-depend-
ent RNA polymerase, 3D, is highly conserved among other 
serotypes and strongly immunogenic, therefore, we selected 
VP1 and 3D as vaccine targets. Methods: VP1 and 3D genes 
were codon-optimized to enhance protein expression level 
and cloned into mammalian expression vector. To produce re-
combinant protein, VP1 and 3D genes were also cloned into 
pET vector. The VP1 and 3D DNA or proteins were co-immu-
nized into 5 weeks old BALB/C mice. Results: Antigen-spe-
cific serum antibody (Ab) responses were detected by Ab 
ELISA. Cellular immune response against VP1 and 3D was 
confirmed by ELISpot assay. Conclusion: The results showed 
that all DNA- and protein-immunized groups induced cellular 
immune responses, suggesting that both DNA and recombi-
nant protein vaccine administration efficiently induced 
Ag-specific humoral and cellular immune responses.
[Immune Network 2009;9(6):265-273]
INTRODUCTION
Foot-and-mouth disease (FMD) is a lethal vesicular disease in 
cloven-hoofed animals, and it infects lung epithelial cells in 
respiratory tract. It is transmitted by air and develops blisters 
rupture,  and  pyrexia  on  mouth  and  feet.  It  is  caused  by 
Foot-and-mouth disease Virus (FMDV) which is a member of 
the  family  Picornaviridae,  genus  Apthovirus,  having  7-8  kb 
positive single-stranded RNA genome (1). Seven immunologi-
cally distinct serotypes have been identified on the basis of 
a VP1 coding region sequence: A, O, C, SAT1, SAT2, SAT3, 
and  Asia1.  Serotype  O  is  prevalent  in  Africa,  Asia,  South 
America, and occasionally Europe. It accounts for over 60% 
of  positive  FMD  isolated  by  The  Food  and  Agriculture 
Organization World Reference Laboratory for Foot-and-Mouth 
Disease  (WRLFMD)  from  2000  to  2004  (2).
    Chemically  inactivated  FMDV  is  used  as  a  commercial 
vaccine. In the early time, formalin and aziridine compounds 
were used widely for inactivation, however, they had a safety 
problem. Later, binary ethyleneimine (BEI) was found to be 
as a more effective reagent, however, it was known to reduce 
efficacy of vaccination (3). Nowadays, many researchers have 
tried to use alternative vaccines which are more safe and ef-
fective  such  as  a  DNA  vaccine  for  replacing  these  conven-FMDV DNA and Protein Vaccines Induce Immune Responses in Mice
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tional  vaccines.
    In case of FMDV, structural protein genes are used as the 
most immunodominant target for DNA vaccine. A highly con-
served Arg-Gly-Asp (RGD) triplet motif, which is located on 
the highly mobile exposed G-H loop of capsid protein VP1, 
has  been  reported  as  a  neutralizing  epitope  site  on  empty 
FMDV capsids which is generated from in vivo infection. Sites 
135∼167 and 141∼160 region (G-H loop) are known as the 
T and B cell epitopes. Moreover, 200∼213 region of carboxyl 
terminus and 43∼44 region of N-terminal also contain B cell 
epitopes (4,5). An expression of MHC class I complex were 
suppressed  in  2∼3  hr  after  virus  infection,  because  virus 
eliminates  translation  initiation  factor  in  host  cells  such  as 
macrophage or dendritic cell in vitro (6). Although VP1 se-
quence  is  highly  variable  among  serotypes  and  VP1  alone 
can’t induce neutralizing antibody (7), DNA vaccine of VP1 
can  protect  mice  from  viral  infection  without  induction  of 
neutralizing antibody (8). Nevertheless, VP1 is less likely to 
induce FMDV-specific T cell response than P1, because it is 
susceptible  to  proteolytic  cleavage.  Viral  structural  proteins 
have a tendency to induce humoral response, whereas non-
structural proteins seem to be more effective in inducing cel-
lular immunity. A 3D, RNA-dependent RNA polymerase has 
a consistent sequence among various serotypes and is known 
as a stimulator of cellular and humoral immune response (9). 
Furthermore, it induces FMDV-specific T cell proliferation and 
delayed-type hypersensitivity (DTH) responses in pigs when 
DNA  vaccine  with  P1  is  introduced  (10).
    Intradermal  injection using  tattoo device  was  reported  as 
an effective delivery system for induction of cellular immunity 
against  viral  infection  (11,12).  Moreover,  antigen  delivery 
through skin is also expected to be effective inducer of the 
innate immune response, because the antigen presenting mol-
ecules on the surface of swine skin dendritic cell (DC), such 
as  swine  major  histocompatibility  complex  class  II  (SLA  II) 
or co-stimulatory molecule CD80/ CD86, are not influenced 
by  FMDV  infection  (13).
  In this study, codon-optimized VP1 and 3D DNA vaccines 
as well as bacterial recombinant proteins VP1 and 3D were 
evaluated  for  their  efficacy  in  mice,  as  determined  by  Ab 
ELISA  and  IFN-γ ELISpot  assay.
MATERIALS AND METHODS
Cell line
RD and 293T cells were grown in Dulbecco’s modified Eagle 
medium (DMEM, Gibco-BRL, Eggenstein, Germany) contain-
ing 10% heat-inactivated fetal bovine serum (FBS, Sigma, St. 
Louis,  US).
Construction of plasmid
VP1 and 3D of FMDV serotype O/otaiwan97 sequence were 
codon optimized for increasing protein expression level. PCR 
primers for each different VP1 and 3D were designed. These 
genes were amplified by conventional PCR amplification pro-
cedure and reaction condition. PCR included 30 cycles of de-
naturation  at  94
oC  for  1  min,  annealing  at  55
oC  for  1  min, 
extension at 72
oC for 1 min, and final extension at 72
oC
  for 
10 min. Amplified PCR products were cloned into pGEM-T 
easy vector (Promega, Madison, USA), and sequences of the 
inserts  were  confirmed  by  sequencing  analysis.  Confirmed 
constructs were subcloned into pcDNA3.1 His/V5 (Invitrogen, 
C a r l s b a d ,  U S A )  a n d  p E T 3 2 a ( ＋)  bacterial  expression  vector 
(Novagen,  Madison,  USA).  The  primer  sequences  used  for 
pcDNA3.1-VP1 cloning were forward 5'-GCCCCCAAGCTTG-
CCGCCACCATGACCAVVTCTGCTGGTGAG-3' and reverse 5'- 
ATCGGGCTCGAGTTTTGCAGGTGCCAC-3'. The primers used 
for  pcDNA3.1-3D  amplification  were  forward  5'-GCCCCC-
AAGCTTGCCGCCACCATGGGTTTGATCGTCGATACC-3'  and 
reverse 5'-ATCGGGCTCGAGCGCGTCACCGCACACGG-3'. The 
VP1 used for cloning into pET32a-VP1 was amplified by PCR. 
The  sequence  of  the  sense  and  antisense  primer  were  5'- 
GCCCCCGGATCCACCACCTCTGCTGGTGAG-3'  and  5'-ATC-
GGGAAGCTTTTTTGCAGGTGCCAC-3', respectively. The pri-
mers  used  for  pET32a-3D  amplification  were  5'-GCCCCC-
GGATCCGGTTTGATCGTCGATAC  C-3'  for  forward  and  5'- 
ATCGGGAAGCTTCGCGTCACCGCACACGG-3' for reverse. For 
DNA immunization, each DNA plasmid was amplified in E. 
coli strain DH5α (Gibco-BRL, Bethesda, USA) and purified 
using an Endofree Plasmid Maxi kit (QIAGEN Inc, Valencia, 
USA).
Expression and purification of recombinant protein in 
E. coli
Plasmids, pET32a-VP1 and pET32a-3D, were transformed into 
E. coli BL21-DE3 competent cells (Gibco-BRL, Gaithersburg, 
USA). The bacteria were cultured in 500 ml LB at 37
oC until 
OD600 reached 0.6. Expression was induced by the addition 
of isopropyl-β-thiogalactopyranoside (IPTG) at a final con-
centration of 0.5 mM and incubated at 37
oC for 3 hrs for 3D 
or 6 hrs for VP1. The cells were harvested and lysed by soni-
cation  on  ice,  followed  by  centrifugation.  The  supernatant FMDV DNA and Protein Vaccines Induce Immune Responses in Mice
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was used for purification of 3D, while the pellet of VP1 was 
solubilized with EDTA-free binding buffer (20 mM Tris-HCl, 
pH  7.9,  0.5  M  NaCl,  8  M  urea)  and  the  cell  debris  was 
discarded. The protein of interest was isolated and purified 
using  ProBond
TM  Columns  (Invitrogen  Corporation,  Carls-
bad, USA) by ProBond purification system with Ni-NTA res-
in  (QIAGEN,  Chatsworth,  USA).  Then,  the  proteins  were 
eluted  with  a  gradient  of  elution  buffer  (20  mM  Tris-HCl, 
pH 7.9, 0.5 M NaCl, 1M imidazole). Eluted protein was stor-
ed  at  −80
oC  until  assay.
Immunofluorescence assay (IFA)
The assay was carried out according to the method previously 
described (14). RD cells at a density of 1.2×10
5 cells were 
subcultured in DMEM in 2-well chamber slide for 16 hrs be-
f o r e  t r a n s f e c t i o n .  D N A  w a s  m i x e d  w i t h  F u g e n e 6  ( R o c h e  
Molecular Biochemicals, Indianapolis, USA) and added drop-
wise to the cell. After 48 hrs of incubation, transfected cells 
were washed with serum-free medium and 1X phosphate buf-
fered  saline  (PBS)  once.  Washed  cells  were  fixed  with  2% 
paraformaldehyde (Sigma Chemical Co., St. Louis, USA) sol-
ution for 30 min and washed three times with 1X PBS. After 
blocking with 10% goat serum in 0.1% Triton X-100 for 30 
min, the cells were incubated with mouse anti-V5 monoclonal 
antibody (Invitrogen, Groningen, The Netherlands) at a 1：
1,000 dilution in 0.1% Triton X-100 with 3% goat serum for 
90 min at room temperature (RT). After washing three times 
with  1X  PBS,  cells  were  incubated  with  fluorescein  iso-
thiocyanate  (FITC)-conjugated  anti-mouse  IgG  antibody 
(Molecular  Probe,  Carlsbad,  USA)  at  a  1：2,500  dilution  in 
0.1% Triton X-100 with 3% goat serum for 90 min at RT. The 
cells  were  washed  three  times  with  1X  PBS.  Washed  cells 
w e r e  i n c u b a t e d  w i t h  4 ’-6-Diamidino-2-phenylindole  (DAPI, 
R o c h e ,  I n d i a n a p o l i s ,  U S )  f o r  1 5  m i n  a t  R T ,  a n d  t h e y  w e r e  
then  washed  extensively  in  1X  PBS  and  a  cover  slip  was 
mounted  over  the  cells  using  mounting  medium  (Shandon, 
Pittsburg, US). The prepared slides were observed under UV 
microscope  (Nikon,  ECLIPSE  TE2000-U,  Tokyo,  Japan).
Western blot analysis
Cells were harvested 48 hrs after transfection with CaPO4 pre-
cipitation using a ProFection Kit (Promega, Madison, WI) and 
lysed with lysis buffer (50 mM Tris-Cl, pH=7.4, 150 mM NaCl, 
1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, pro-
tease inhibitor cocktail). The cell lysate in 3 X SDS loading 
buffer was boiled for 5 min and electrophoresed through 10% 
SDS-PAGE gel. Resolved proteins were transferred to a nitro-
cellulose  membrane  and  the  membrane,  was  blocked  with 
5% milk protein in TBST (10 mM Tris-HCl, pH 8.0, 150 mM 
NaCl, 0.05% Tween 20) for 4 hrs at RT. The membrane was 
incubated with an anti-V5 monoclonal antibody (Invitrogen, 
Groningen, The Netherlands) in the blocking solution for 2 
hrs at RT and washed in TBST. Washed membrane was in-
cubated with HRP-conjugated anti-mouse IgG antibody (Mo-
lecular Probe, Carlsbad, USA) in the blocking solution for 1 
hr at RT, washed, and developed using ECL kit (AbFrontier, 
Seoul,  Korea).
Generation of anti-peptide antibodies in rabbit
P e pt id es  fo r V P1  a nd  3D  w e re  s yn t he si ze d  o n t he  b as is o f 
B cell epitope prediction and immunized into rabbits to raise 
VP1- and 3D-specific antisera. Rabbits were injected with 200
μg each of different peptides in Freund’s complete adjuvant 
(FCA, Sigma, USA), followed by two boosting immunizations 
at 4-week intervals according to conventional immunization 
scheme.
Immunizations to mice
Six  to  eights  weeks  old  female  BALB/c  mice  were  divided 
into several groups (4 mice/group) for the DNA or protein 
immunization
  a .  I n t r a m u s c u l a r  ( i . m . )  i m m u n i z a t i o n
    Mice were immunized with total 10μg of purified protein 
via intramuscular (i.m.) route at 2 weeks interval. Group 1 
was immunized with VP1 and 3D protein. Group 2 was im-
munized with PBS as a negative control. Mice were immu-
nized 8 times from days 0. The splenocytes were harvested 
3  weeks  after  the  last  boosting  for  analysis.
    b.  Intradermal  (i.d.)  immunization
    Mice were immunized 3 times in one cycle at 3 days inter-
val with total 20μg of naked plasmid via i.d. route admin-
istration  using tattoo  device.  Group 1 was immunized with 
pcDNA-VP1/-3D,  which  Group  2  was  immunized  with  pc-
DNA3.1 empty vector as a negative control. Mice were immu-
nized 6 cycles with 3 times per each cycle from days 0. The 
splenocytes  were  harvested  3  weeks  after  the  last  boosting 
for  analysis.
ELISA (Enzyme-linked immunosorbent assay)
An  induction  of  antibodies  in  immunized  mice  was  de-
termined  using  an  enzyme-linked  immunosorbent  assay 
(ELISA). A 96-well EIA/RIA plate (Corning Incorporated Co-FMDV DNA and Protein Vaccines Induce Immune Responses in Mice
Ji-young Bae, et al.
268 IMMUNE NETWORK http://www.ksimm.or.kr Volume 9 Number 6 December 2009
Figure 1. FMDV type-O VP1, 3D cloning strategy and in vitro protein expression. FMDV VP1 (0.6 Kb) and 3D (1.4 Kb) PCR products were 
subcloned into pcDNA3.1V5/His mammalian expression vector and pET bacterial expression vector. (A) FMDV type-O VP1 and 3D cloning 
strategy (B) Protein expression of VP1 and 3D was determined in plasmids-transected RD cells, and its expression was visualized by FITC-labeling 
and DAPI staining for nucleus. (C) 293T cells were transiently transfected with pcDNA-VP1 (lane 1) and pcDNA-3D (lane 2) plasmids, and the 
expression was confirmed by Western blot analysis.
st ar ,  L ow e ll,  M A ,  U S ) wa s co at e d w it h  5μg/ml of purified 
protein in PBST (1X PBS, pH 7.4, 0.05% Tween-20) for 16 
hrs at 4
oC. The plates were blocked with 3% bovine serum 
albumin (BSA) in PBST for 1 hr at 37 
oC. After washing, 50μl 
of sera (diluted 1：50) were added and incubated for 1 hr 
at 37
oC. Bound antibodies were detected with HRP-conjugated FMDV DNA and Protein Vaccines Induce Immune Responses in Mice
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Figure 2. Purification of recombi-
nant VP1 and 3D proteins, and bio-
logical activity of B cell epitope 
peptide polyclonal Ab. (A) pET-VP1
(lane 1) and -3D (lane 2) ex-
pressions in bacterial system were 
confirmed by Coomassie staining 
of SDS-PAGE gel. (B) The purified 
VP1 (lane 1) and 3D (lane 2) pro-
teins were confirmed by B cell epit-
ope peptide -specific polyclonal 
Abs.
anti-mouse  IgG  antibody  and  substrate  TMB  (3,3’,5,5’-tetra-
methylbenzidine) buffer solution (Sigma, St. Louis, USA). Color 
reaction was stopped by adding 2M sulfuric acid, and an ab-
s o r b a n c e  w a s  m e a s u r e d  a t  4 5 0  n m  u s i n g  a u t o m a t e d  p l a t e  
reader  Bench  mark  plus  system  (Bio-Rad,  Hercules,  USA).
ELISPOT assay
All reagents for ELISpot assay was purchased from BD Biosci-
ences  (Franklin  Lakes,  USA),  unless  otherwise  specified. 
BD
TM  ELISOPT  Plates  were  coated  with  100μl  of  Purified 
Anti-mouse IFN-γ antibody at a concentration of 5μg/ml in 
sterile PBS overnight at 4
oC. Coated plates were then washed 
once with 200μl of RPMI 1640 (Sigma, St. Louis, USA) con-
t a i n i n g  1 0 %  F B S  ( S i g m a ,  S t .  L o u i s ,  U S A )  a n d  1 %  P e n i c i l -
lin-Streptomycin  (Gibco-BRL,  Gaithersburg,  USA),  and  then 
blocked with 200μl of RPMI 1640 complete medium for 2 
h at RT. The splenocytes were harvested from mice at one 
week after the last boosting, by grinding the spleen in RPMI 
1640 containing 5% FBS and 1% pen/strep, and RBC was re-
moved  using  Gey’s  medium.  Cell  suspension  was  centri-
f u g e d ,  a n d  t h e  c e l l  p e l l e t  w a s  r e s u s p e n d e d  i n  1 0 %  R P M I  
1640. Splenocytes were prepared at density of 4×10
5 cells/ 
well  in  10%  RPMI  medium,  and  they  were  stimulated  with 
various  peptides  (10μg/ml)  for  48  hrs,  and  sequentially 
washed with deionized (DI) water, and PBS containing 0.05% 
Tween-20 for 3-5 min per each. One hundred μl of 2μg/ml 
biotinylated  anti-mouse  IFN-γ in  PBS  containing  10%  FBS 
was  added  to  each  well  and  incubated  for  2  hrs  at  RT. 
Unbound  antibody  solution  was  discarded,  and  the  precip-
itate was washed three times with 200μl of washing buffer 
(PBS  containing  0.05%  Tween-20).  One  hundred  μl of di-
luted streptavidin-HRP in PBS containing 10% FBS was added 
to per each well, and they were incubated for 1 hr at RT. 
And they were then washed 4 times with washing buffer for 
1∼2 min each, and were further washed twice with 200μl 
of 1X PBS. Finally, 100μl of Final Substrate Solution, BDTM 
AEC  Substrate  Reagent  Set  were  added  to  each  well.  The 
plate was monitored for spot development from 60 min after 
incubation, so as not to be over-developed, and the reaction 
was stopped by washing wells with DI water. The plate was 
air-dried  overnight  at  RT  until  being  completely  dried.  Re-
moval  of  plastic  tray  under  plate  will  facilitate  drying.  The 
plate was stored in a sealed plastic bag in the dark until being 
analyzed. The number of spots per well was determined us-
ing a KS ELISPOT Automated Reader System with KS ELISPOT 
4.2  Software  (Carl  Zeiss,  Inc.  Thornwood,  USA).
RESULTS
VP1 and 3D proteins are expressed in mammalian 
cells
Recombinant  FMDV  type  O  VP1  and  3D  genes  were  gen-
erated by overlapping PCR as illustrated in Fig. 1A. After con-
f i r m i n g  s e q u e n c e  o f  D N A ,  t h e  D N A s  w e r e  l i g a t e d  i n t o  
pcDNA3.1 V5/His vector. The expression of the VP1 and 3D 
proteins in mammalian cells was determined by an IFA and 
Western blot analysis (Fig. 1). According to the Ag-specific 
signal,  both  VP1  and  3D  proteins  were  found  to  the  ex-
pressed in the cytoplasm of RD cells (Fig. 1B). However, no 
signals of pcDNA-transfected cells were detected. The 293T 
cell  lysates  of  VP1  and  3D  were  harvested  after  48  hrs  of 
transfection, and were analyzed by Western blot analysis, us-
ing  mouse  anti-V5  antibody.  As  shown  in  Fig.  1C,  the  ex-
pected molecular weights of the pcDNA-VP1 and pcDNA-3D 
were  26.9  kDa  and  56.2  kDa,  respectively.FMDV DNA and Protein Vaccines Induce Immune Responses in Mice
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Figure 3. Humoral immune responses in DNA vaccine-immunized mice. (A) In vivo DNA immunization scheme (B) The antigen-specific serum
IgG responses in Balb/c mice after co-immunization with pcDNA-VP1 and pcDNA-3D at two different time points (□ 2 wks p.i., ■ 5 wks
p.i.). (C) IgG isotyping analysis with sera harvested from the group at 9 wks from the first immunization and tested for antibodies at 1：50
dilution. (□ IgG1,  ■ IgG2a). The result was obtained from averages of groups against each antigen. The data represent average±S.D.
Purification of recombinant VP1 and 3D proteins 
from bacterial system and biological activity of 
anti-B cell epitope peptide polyclonal antibody 
raised in rabbit
When both VP1 and 3D proteins were expressed in BL21-DE3 
c e l l s ,  o n l y  3 D  p r o t e i n  w a s  e x p r e s s e d  a s  a  s o l u b l e  f o r m .  
However, VP1 was expressed as an inclusion body and puri-
fied as a native form using hybrid purification method and 
used for a production of B-cell epitope-specific Abs. The VP1 
and  3D  protein  bands  on  Coomassie  stained  gel  were  de-
t e c t e d  w i t h  a  m o l e c u l a r  w e i g h ts,  corresponding  to  42  kDa 
(lane 1) and 72.8 kDa (lane 2), respectively (Fig. 2A). The 
VP1 and 3D B-cell epitope peptides were predicted, synthe-
sized and immunized into rabbits. The purified proteins were 
confirmed by Western blot analysis using the VP1 or 3D B 
cell epitope peptide-specific polyclonal Abs which had been 
raised from rabbits. Fig. 2B shows that the recombinant VP1 
and 3D proteins can be detected by the polyclonal Abs. The 
anti-B cell epitope polyclonal antibodies were used in ELISA 
for  confirmation  of  activity.
DNA and recombinant protein vaccines for FMD 
induced humoral and cellular immune responses in 
mice
Mice (BALB/c) were immunized with 10μg of both pcDNA- 
VP1 and pcDNA-3D plasmids, or 10μg of both recombinant 
protein of VP1 and 3D. The mice sera were then harvested 
at 2 and 5 weeks post-immunization, and serum IgG levels 
were determined accoding to in vivo schedule (Fig. 3A). The 
levels  of  the  humoral  immune  responses  not  only  in  the 
group  co-immunized  with  VP1  and  3D  DNA  plasmid  (Fig. 
3B), but also in the group co-immunized with VP1 and 3D 
protein  (Fig.  4B)  showed  higher  titer  of  Ag-specific  serum 
IgG than the mice immunized with pcDNA empty vector or 
PBS. The humoral immune responses were detected in the 
sera of all DNA- or protein-immunized groups as early as 2 
weeks after the first immunization, and 3D-specific serum IgG 
level was increased dose-dependently in both 3D-DNA and- FMDV DNA and Protein Vaccines Induce Immune Responses in Mice
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Figure 5. Cellular immune response in DNA vaccine-immunized mice.
Numbers of IFN-γ secreting cell spots from a pool of 4 mice 
splenocytes (4×10
5 cells/well) were determined by recall Ag VP1 or 
3D protein stimulation. The splenocytes were pooled from 4 mice 
harvested 3 weeks after the last vaccination with VP1 and 3D DNA. 
The ELISpot assay was performed after stimulating the cells with 10μg/
ml each of the recombinant proteins for 48 hrs.
Figure 4. Humoral immune responses in protein vaccine-immunized mice. (A) In vivo protein immunization scheme (B) The antigen-specific
serum IgG responses in Balb/c mice after immunization against VP1 or 3D protein at two different time points. (□ 2 wks p.i., ■ 5 wks p.i.)
(C) IgG isotyping analysis with sera from the group sampled at 7 wks from the first immunization and tested for antibodies at 1：50 dilution 
(□ IgG1,  ■ IgG2a). The result was obtained from averages of four mice in each group. The data represent average±S.D.
protein immunized groups (Fig. 3B, 4B). IgG isotyping analy-
sis with the sera at 9 weeks post-immunization showed that 
IgG2a/IgG1  ratio  was  slightly  larger  than  1.  Therefore, 
VP1/3D  DNA  or  protein  vaccine  seemed  likely  to  induce 
Th1-dependent  humoral  immune  response  (Fig.  3C,  4C).
  Cell-mediated immune response was determined by count-
ing IFN-γ secreting cell number by ELISpot analysis. Fig. 5 
shows that in DNA-immunized group, only 3D-specific IFN-
γ secreting cells were stimulated, but not in VP1 or pcDNA. 
When  VP1/3D  proteins  were  co-immunized  into  mice,  the 
IFN-γ secretion was antigen-specifically induced by both VP1 
and  3D  (Fig.  6).
DISCUSSION
In this study, recombinant DNA and protein vaccination ap-
proach was successfully achieved by co-administration of the 
FMDV type O VP1/3D, which contains both the B cell and 
T cell epitopes. The nucleotide sequences were codon-opti-FMDV DNA and Protein Vaccines Induce Immune Responses in Mice
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Figure 6. Cellular immune responses in proteins vaccine-immunized
mice. Numbers of IFN-γ secreting cell spots from a pool of 4 mice 
splenocytes (4×10
5 cells/well) were determined by recall Ag VP1 or 
3D protein stimulation. The splenocytes were pooled from 4 mice 
harvested 3 weeks after the last vaccination with VP1 and 3D protein.
The ELISpot assay was performed after stimulating the cells with 10μg/
ml each of the recombinant proteins for 48 hrs.
mized, and its expression was confirmed in both mammalian 
cells and bacterial system. The purified proteins were found 
to be immunogenic and to have preserved B-cell epitope. In 
vivo study showed that VP1 and 3D-specific serum IgG were 
detected as early as 2 weeks after the first immunization and 
increased dose-dependently thereafter in both 3D-DNA and- 
protein immunized groups (Fig. 3, 4). Recombinant protein 
vaccine  induced  higher  level  of  humoral  immune  response 
than naked DNA vaccine. Furthermore, the IgG2a/ IgG1 ratio 
in the sera from the mice co-immunized with either pcDNA 
VP1/3D  or  recombinant  VP1  and  3D  protein  was  slightly 
higher  than  1.  In  general,  such  pattern  is  typical  in  the 
Th1-dependent immune response. It was reported that DNA 
plasmid  encoding  P1  induces  Th2-dependent  immune  re-
sponse,  whereas  VP1  induces  Th1-dependent  humoral  im-
mune response (15). However, Park et al. showed that VP1 
induces Th2-dependent immune response, when VP1 plasmid 
was coadministered with IL-1α via  tail  vein  injection  (16). 
Therefore, it seems to be important to choose molecular ad-
juvants  to  co-administer  with  VP1  for  skewing  immune 
responses.  When  the  VP1  sequence  which  contains  only 
B-cell epitope and non-structural protein (NSP) (17) or trans-
genic membrane-anchored VP1 (7) was immunized, the pro-
tection level was  very  low  inspite of higher total Ab level. 
Soluble recombinant VP1 protein produced from E. coli also 
showed T-cell immune response and protection without gen-
erating neutralizing antibody (5). Furthermore, co-immuniza-
tion  of  DNA  plasmid  encoding  VP1  which  contained  all  of 
the epitopes and NSP containing the T-cell epitope showed 
partial protection effect in guinea pig (18), or anti-viral pro-
tection effect irrespective of presence of neutralizing antibody 
titers  (8).
    ELISpot data detected IFN-γsecreting cells after stimulation 
with VP1 and 3D recall antigen, indicating that antigen-spe-
cific CD4＋ T cell activation was induced in DNA or protein 
immunization (Fig. 5, 6). Only the mice immunized with VP1 
DNA failed to stimulate the IFN-γ secreting cells when stimu-
lated with recombinant VP1 protein (Fig. 5). It is, therefore, 
possible that the binding of VP1 RGD region to the cellular 
receptor interferes with the recognition of the T cell epitope 
(19). While VP1 induces humoral immune response, 3D in-
duces  cellular  immune  response  more  strongly.
    In conclusion, the codon-optimized VP1, 3D DNA and re-
combinant proteins are strong immunogen to mice even with 
smaller amount. Especially, Ag-specific humoral and cellular 
immune responses were induced as early as 2 weeks post-im-
munization by using tattoo device. DNA vaccine is one of the 
better-defined  subunit  vaccine,  and  has  better  strategies  to 
overcome many problems than protein vaccine, such as gly-
cosylation,  toxicity, cost or lack of the  CTL activation (20). 
In order to compensate the weak and short-period immune 
responses  generated  by  DNA  vaccine,  however,  strong  ad-
juvant  molecules  or  powerful  delivery  tools  are  necessary. 
Our future research is aimed to construct both VP1 and 3D 
fusion plasmid and molecular adjuvant for induction of higher 
cellular immune response against VP1 and protective efficacy. 
Moreover,  other  delivery  system  such  as  electroporation 
would be worth to be considered. Finally, it is also necessary 
to evaluate protective immune response induced by DNA and 
protein vaccination, and elucidate the immune cells involved 
in  anti-viral  infection.
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